|
MXPA02011625A
(es)
*
|
2000-05-26 |
2003-03-27 |
Schering Corp |
Antagonistas receptores de adenosina a2a.
|
|
WO2003022283A1
(en)
*
|
2001-09-13 |
2003-03-20 |
Schering Corporation |
Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
|
|
AR037243A1
(es)
|
2001-10-15 |
2004-11-03 |
Schering Corp |
Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
|
|
FR2832405B1
(fr)
*
|
2001-11-19 |
2004-12-10 |
Sanofi Synthelabo |
Tetrahydropyridyl-alkyl-heterocycles azotes, procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
TW200300686A
(en)
|
2001-11-30 |
2003-06-16 |
Schering Corp |
Adenosine A2a receptor antagonists
|
|
AU2002352933A1
(en)
|
2001-11-30 |
2003-06-17 |
Schering Corporation |
[1,2,4]-triazole bicylic adenosine A2a receptor antagonists
|
|
ATE453647T1
(de)
*
|
2001-11-30 |
2010-01-15 |
Schering Corp |
Adenosin a2a rezeptor antagonisten
|
|
KR20100056569A
(ko)
|
2002-01-28 |
2010-05-27 |
교와 핫꼬 기린 가부시키가이샤 |
운동성 질환에 걸린 환자의 치료 방법
|
|
HK1082662A1
(zh)
*
|
2002-05-30 |
2006-06-16 |
King Pharmaceuticals Research And Development Inc. |
具有三环吡唑并三唑并嘧啶环结构的制药活性化合物及其使用方法
|
|
NZ540493A
(en)
*
|
2002-12-19 |
2008-04-30 |
Schering Corp |
Uses of adenosine A2a receptor antagonists
|
|
US20060106040A1
(en)
*
|
2002-12-19 |
2006-05-18 |
Michael Grzelak |
Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
|
|
EP1618109A2
(en)
|
2003-04-09 |
2006-01-25 |
Biogen Idec MA Inc. |
Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
|
|
EP1622912B1
(en)
*
|
2003-04-23 |
2009-05-27 |
Schering Corporation |
2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
|
|
KR20060037252A
(ko)
*
|
2003-06-10 |
2006-05-03 |
교와 핫꼬 고교 가부시끼가이샤 |
불안 장애의 치료 방법
|
|
WO2004111004A1
(en)
*
|
2003-06-12 |
2004-12-23 |
Novo Nordisk A/S |
Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase
|
|
WO2005039506A2
(en)
*
|
2003-10-24 |
2005-05-06 |
Exelixis, Inc. |
P70s6 kinase modulators and method of use
|
|
JP4782693B2
(ja)
|
2003-10-28 |
2011-09-28 |
シェーリング コーポレイション |
置換５−アミノ−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ［１，５−ｃ］ピリミジンを調製するためのプロセス
|
|
CA2547248A1
(en)
|
2003-12-01 |
2005-06-16 |
Schering Corporation |
Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
|
|
US20060009504A1
(en)
*
|
2003-12-19 |
2006-01-12 |
Schering Corporation |
Pharmaceutical compositions
|
|
US7709492B2
(en)
*
|
2004-04-21 |
2010-05-04 |
Schering Corporation |
Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
|
|
EP2258372B8
(en)
|
2005-06-07 |
2012-12-19 |
Kyowa Hakko Kirin Co., Ltd. |
A2A antagonists for use in the treatment of motor disorders
|
|
CA2622741A1
(en)
|
2005-09-19 |
2007-03-29 |
Schering Corporation |
2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
|
|
AR056080A1
(es)
|
2005-09-23 |
2007-09-19 |
Schering Corp |
7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
|
|
ES2273599B1
(es)
|
2005-10-14 |
2008-06-01 |
Universidad De Barcelona |
Compuestos para el tratamiento de la fibrilacion auricular.
|
|
EP2040698A4
(en)
*
|
2006-07-14 |
2011-08-10 |
Shionogi & Co |
OXIM CONNECTIONS AND ITS USE
|
|
TW200840566A
(en)
*
|
2006-12-22 |
2008-10-16 |
Esteve Labor Dr |
Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
|
|
US7723343B2
(en)
|
2007-03-30 |
2010-05-25 |
King Pharmaceuticals Research And Development, Inc. |
Adenosine A2A receptor antagonists
|
|
US8669260B2
(en)
*
|
2008-02-29 |
2014-03-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Ketoconazole-derivative antagonist of human pregnane X receptor and uses thereof
|
|
JP2011513417A
(ja)
|
2008-03-04 |
2011-04-28 |
シェーリング コーポレイション |
アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
|
|
US20110064671A1
(en)
|
2008-03-10 |
2011-03-17 |
Cornell University |
Modulation of blood brain barrier permeability
|
|
TWI473614B
(zh)
*
|
2008-05-29 |
2015-02-21 |
Kyowa Hakko Kirin Co Ltd |
Anti-analgesic inhibitors
|
|
BRPI0916203A2
(pt)
|
2008-07-23 |
2018-05-15 |
Kyowa Hakko Kirin Co Ltd |
agente terapêutico e/ou preventivo para enxaqueca, método para tratar e/ou prevenir enxaqueca, e, uso de um composto
|
|
US20100093702A1
(en)
*
|
2008-10-13 |
2010-04-15 |
Barbay J Kent |
METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
|
|
CA2748174A1
(en)
|
2008-12-30 |
2010-07-08 |
Arqule, Inc. |
Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
|
|
US20120053182A1
(en)
|
2009-01-20 |
2012-03-01 |
Schering Corporation |
Methods of alleviating or treating signs and/or symptoms associated with moderate to severe parkinson's disease
|
|
US8993808B2
(en)
|
2009-01-21 |
2015-03-31 |
Oryzon Genomics, S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
|
US8859566B2
(en)
|
2009-03-13 |
2014-10-14 |
Advinus Therapeutics Private Limited |
Substituted fused pyrimidine compounds
|
|
WO2010114894A1
(en)
|
2009-03-31 |
2010-10-07 |
Arqule, Inc. |
Substituted heterocyclic compounds
|
|
US8537177B2
(en)
*
|
2009-06-15 |
2013-09-17 |
Marvell World Trade Ltd. |
System and methods for gamut bounded saturation adaptive color enhancement
|
|
US8598343B2
(en)
|
2009-08-07 |
2013-12-03 |
Merck Sharp & Dohme Corp. |
Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
|
|
US8859555B2
(en)
|
2009-09-25 |
2014-10-14 |
Oryzon Genomics S.A. |
Lysine Specific Demethylase-1 inhibitors and their use
|
|
US8946296B2
(en)
|
2009-10-09 |
2015-02-03 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
|
|
WO2011101861A1
(en)
|
2010-01-29 |
2011-08-25 |
Msn Laboratories Limited |
Process for preparation of dpp-iv inhibitors
|
|
WO2011106105A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Inhibitors for antiviral use
|
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
|
RU2599248C2
(ru)
|
2010-04-19 |
2016-10-10 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
|
US9006449B2
(en)
|
2010-07-29 |
2015-04-14 |
Oryzon Genomics, S.A. |
Cyclopropylamine derivatives useful as LSD1 inhibitors
|
|
ME03085B
(me)
|
2010-07-29 |
2019-01-20 |
Oryzon Genomics Sa |
Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena
|
|
JP5843869B2
(ja)
*
|
2010-09-24 |
2016-01-13 |
アドヴィナス・セラピューティックス・リミテッド |
アデノシン受容体拮抗薬としての縮合三環化合物
|
|
US9061966B2
(en)
|
2010-10-08 |
2015-06-23 |
Oryzon Genomics S.A. |
Cyclopropylamine inhibitors of oxidases
|
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
|
EP3981395A1
(en)
|
2011-02-08 |
2022-04-13 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
|
WO2012129381A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Concert Pharmaceuticals Inc. |
Deuterated preladenant
|
|
WO2012127472A1
(en)
*
|
2011-03-22 |
2012-09-27 |
Mapi Pharma Ltd. |
Process and intermediates for the preparation of preladenant and related compounds
|
|
WO2013024474A1
(en)
*
|
2011-08-18 |
2013-02-21 |
Mapi Phrarma Ltd. |
Polymorphs of preladenant
|
|
BR112014009238B1
(pt)
|
2011-10-20 |
2022-08-09 |
Oryzon Genomics S.A. |
Compostos de (hetero)aril ciclopropilamina, seus usos e composições farmacêuticas
|
|
BR112014009306B1
(pt)
|
2011-10-20 |
2021-07-20 |
Oryzon Genomics S.A. |
Compostos de (hetero)aril ciclopropilamina como inibidores de lsd1
|
|
WO2014071512A1
(en)
*
|
2012-11-06 |
2014-05-15 |
Universite Laval |
Combination therapy and methods for the treatment of respiratory diseases
|
|
WO2014101120A1
(en)
*
|
2012-12-28 |
2014-07-03 |
Merck Sharp & Dohme Corp. |
Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
|
|
CN107106558A
(zh)
|
2014-11-18 |
2017-08-29 |
默沙东公司 |
具有a2a拮抗剂性质的氨基吡嗪化合物
|
|
US10138212B2
(en)
|
2015-02-06 |
2018-11-27 |
Merck Sharp & Dohme Corp. |
Aminoquinazoline compounds as A2A antagonist
|
|
EP3307067B1
(en)
|
2015-06-11 |
2022-11-02 |
Merck Sharp & Dohme LLC |
Aminopyrazine compounds with a2a antagonist properties
|
|
WO2017008205A1
(en)
|
2015-07-10 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Substituted aminoquinazoline compounds as a2a antagonist
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
RS63557B1
(sr)
*
|
2017-03-30 |
2022-10-31 |
iTeos Belgium SA |
Derivati 2-okso-tiazola kao inhibitori a2a i jedinjenja za upotrebu u lečenju kancera
|
|
WO2018178338A1
(en)
*
|
2017-03-30 |
2018-10-04 |
Iteos Therapeutics |
2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
|
|
US11498923B2
(en)
|
2017-12-13 |
2022-11-15 |
Merck Sharp & Dohme Llc |
Substituted imidazo[1,2-c]quinazolines as A2A antagonists
|
|
EP3735413B1
(en)
*
|
2018-01-04 |
2022-07-06 |
Impetis Biosciences Ltd. |
Tricyclic compounds, compositions and medicinal applications thereof
|
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
|
CN108276345A
(zh)
*
|
2018-03-22 |
2018-07-13 |
重庆奥舍生物化工有限公司 |
一种药物中间体嘧啶-5-甲醛的制备方法
|
|
WO2019196803A1
(en)
*
|
2018-04-08 |
2019-10-17 |
Beigene, Ltd. |
Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
CN108864114B
(zh)
*
|
2018-06-04 |
2020-11-06 |
应世生物科技(南京)有限公司 |
选择性a2a受体拮抗剂
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
CN110742893B
(zh)
*
|
2018-07-23 |
2024-04-05 |
百济神州(北京)生物科技有限公司 |
A2a受体拮抗剂治疗癌症的方法
|
|
US11312719B2
(en)
|
2018-11-30 |
2022-04-26 |
Merck Sharp & Dohme Corp. |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
|
|
AU2019401649B2
(en)
|
2018-12-20 |
2025-08-28 |
Incyte Corporation |
Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
US12325708B2
(en)
|
2019-05-03 |
2025-06-10 |
Nektar Therapeutics |
Adenosine 2 receptor antagonists
|
|
DE102019116986A1
(de)
|
2019-06-24 |
2020-12-24 |
Helmholtz-Zentrum Dresden-Rossendorf E. V. |
Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
|
|
US20230024108A1
(en)
*
|
2019-07-17 |
2023-01-26 |
Teon Therapeutics, Inc. |
Adenosine a2a receptor antagonists
|
|
CN111825698B
(zh)
|
2019-07-30 |
2021-10-15 |
杭州阿诺生物医药科技有限公司 |
腺苷受体拮抗剂
|
|
CN112028891B
(zh)
|
2019-07-30 |
2022-07-05 |
厦门宝太生物科技股份有限公司 |
腺苷受体拮抗剂
|
|
CN111072675A
(zh)
*
|
2019-12-12 |
2020-04-28 |
广东东阳光药业有限公司 |
含氮稠合三环衍生物及其用途
|
|
CN113773327B
(zh)
*
|
2021-09-13 |
2022-07-15 |
八叶草健康产业研究院(厦门)有限公司 |
一种吡唑并嘧啶并三唑环类化合物的制备方法
|
|
CN118812539B
(zh)
*
|
2024-06-19 |
2025-11-28 |
苏州大学 |
一种5-氨基三唑并嘧啶衍生物及其制备方法
|
|
CN118812544A
(zh)
*
|
2024-06-19 |
2024-10-22 |
厦门大学 |
一种腺苷a2ar靶向小分子化合物、核素标记探针及其制备方法、应用和药物组合物
|